CN103689599A - 增强免疫力的保健食品及其制备方法 - Google Patents
增强免疫力的保健食品及其制备方法 Download PDFInfo
- Publication number
- CN103689599A CN103689599A CN201310729930.6A CN201310729930A CN103689599A CN 103689599 A CN103689599 A CN 103689599A CN 201310729930 A CN201310729930 A CN 201310729930A CN 103689599 A CN103689599 A CN 103689599A
- Authority
- CN
- China
- Prior art keywords
- preparation
- coix seed
- immunity
- add
- health food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000036039 immunity Effects 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 230000002708 enhancing effect Effects 0.000 title abstract description 11
- 235000013305 food Nutrition 0.000 title abstract description 5
- 244000077995 Coix lacryma jobi Species 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- 240000005373 Panax quinquefolius Species 0.000 claims description 25
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 19
- 235000013402 health food Nutrition 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 16
- 230000006870 function Effects 0.000 abstract description 14
- 210000000822 natural killer cell Anatomy 0.000 abstract description 8
- 206010057249 Phagocytosis Diseases 0.000 abstract description 4
- 230000008782 phagocytosis Effects 0.000 abstract description 4
- 240000004638 Dendrobium nobile Species 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 2
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 230000003833 cell viability Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 210000003024 peritoneal macrophage Anatomy 0.000 abstract 1
- 210000000582 semen Anatomy 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 26
- 210000000952 spleen Anatomy 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 239000013642 negative control Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 239000000284 extract Substances 0.000 description 16
- 238000000605 extraction Methods 0.000 description 14
- 230000000242 pagocytic effect Effects 0.000 description 13
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 13
- 229930182490 saponin Natural products 0.000 description 13
- 150000007949 saponins Chemical class 0.000 description 13
- 238000003304 gavage Methods 0.000 description 12
- 210000002540 macrophage Anatomy 0.000 description 12
- 229920001282 polysaccharide Polymers 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 150000004676 glycans Chemical class 0.000 description 11
- 239000005017 polysaccharide Substances 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 230000033228 biological regulation Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000036541 health Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 206010013183 Dislocation of vertebra Diseases 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000000890 drug combination Substances 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 230000003014 reinforcing effect Effects 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 108010062580 Concanavalin A Proteins 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 2
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000000976 ink Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 229960000716 tonics Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010065369 Burnout syndrome Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000209205 Coix Species 0.000 description 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001808 coupling effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/198—Dry unshaped finely divided cereal products, not provided for in groups A23L7/117 - A23L7/196 and A23L29/00, e.g. meal, flour, powder, dried cereal creams or extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组 别 | n | Con A (cpm) |
阴性对照组 | 10 | 13568±2186 |
低剂量组 | 10 | 9054±1856* |
中剂量组 | 10 | 7695±1547* |
高剂量组 | 10 | 5385±1225* |
组 别 | n | 左右耳重量差值(*10-3) |
阴性对照组 | 10 | 8.76±3.19 |
低剂量组 | 10 | 10.86±2.38 |
中剂量组 | 10 | 12.52±2.68* |
高剂量组 | 10 | 14.76±3.23* |
组 别 | n | 抗体形成细胞 |
阴性对照组 | 10 | 5.02±0.13 |
低剂量组 | 10 | 5.21±0.18 |
中剂量组 | 10 | 5.95±0.21* |
高剂量组 | 10 | 6.28±0.19* |
组 别 | n | 血清HC50 |
阴性对照组 | 10 | 123 |
低剂量组 | 10 | 228* |
中剂量组 | 10 | 276* |
高剂量组 | 10 | 305* |
组 别 | n | 碳廓清吞噬指数 | 吞噬百分数/% | 吞噬指数 |
阴性对照组 | 10 | 4.43±0.76 | 34.33±10.83 | 0.45±0.14 |
低剂量组 | 10 | 5.02±0.86 | 35.28±14.20 | 0.47±0.12 |
中剂量组 | 10 | 4.89±0.73 | 53.58±15.36* | 0.61±0.17* |
高剂量组 | 10 | 5.71±0.58* | 57.89±16.22* | 0.66±0.15* |
组 别 | n | 杀伤率(%) |
阴性对照组 | 10 | 43.2±4.5 |
低剂量组 | 10 | 61.7±6.5* |
中剂量组 | 10 | 69.5±3.3* |
高剂量组 | 10 | 71.4±7.8* |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310729930.6A CN103689599B (zh) | 2013-12-26 | 2013-12-26 | 增强免疫力的保健食品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310729930.6A CN103689599B (zh) | 2013-12-26 | 2013-12-26 | 增强免疫力的保健食品及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103689599A true CN103689599A (zh) | 2014-04-02 |
CN103689599B CN103689599B (zh) | 2015-04-29 |
Family
ID=50351387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310729930.6A Active CN103689599B (zh) | 2013-12-26 | 2013-12-26 | 增强免疫力的保健食品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103689599B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1457808A (zh) * | 2002-05-14 | 2003-11-26 | 上海市中药研究所 | 一种铁皮石斛复方制剂及制备和应用 |
CN1559518A (zh) * | 2004-02-23 | 2005-01-05 | 南京中科生化技术有限公司 | 一种抑制肿瘤的复合人参皂甙生物制剂及制备方法 |
CN101305801A (zh) * | 2008-06-17 | 2008-11-19 | 陶国闻 | 金钗石斛洋参胶囊 |
CN101757453A (zh) * | 2010-03-03 | 2010-06-30 | 澳诺(中国)制药有限公司 | 参芝石斛制剂及其制备方法 |
CN102907670A (zh) * | 2012-10-22 | 2013-02-06 | 广西壮族自治区农业科学院农产品加工研究所 | 一种复方铁皮石斛西洋参含片及其制备方法 |
-
2013
- 2013-12-26 CN CN201310729930.6A patent/CN103689599B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1457808A (zh) * | 2002-05-14 | 2003-11-26 | 上海市中药研究所 | 一种铁皮石斛复方制剂及制备和应用 |
CN1559518A (zh) * | 2004-02-23 | 2005-01-05 | 南京中科生化技术有限公司 | 一种抑制肿瘤的复合人参皂甙生物制剂及制备方法 |
CN101305801A (zh) * | 2008-06-17 | 2008-11-19 | 陶国闻 | 金钗石斛洋参胶囊 |
CN101757453A (zh) * | 2010-03-03 | 2010-06-30 | 澳诺(中国)制药有限公司 | 参芝石斛制剂及其制备方法 |
CN102907670A (zh) * | 2012-10-22 | 2013-02-06 | 广西壮族自治区农业科学院农产品加工研究所 | 一种复方铁皮石斛西洋参含片及其制备方法 |
Non-Patent Citations (2)
Title |
---|
杨明晶等: "铁皮枫斗西洋参胶囊对小鼠免疫调节功能的影响", 《江苏预防医学》, vol. 19, no. 4, 15 December 2008 (2008-12-15), pages 11 - 13 * |
甄永苏等: "《抗肿瘤药物研究与开发》", 30 September 2004, article "金氏公式法", pages: 751 * |
Also Published As
Publication number | Publication date |
---|---|
CN103689599B (zh) | 2015-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10820615B2 (en) | Powder formulation having a function of enhancing immunity and method for preparing the same | |
CN102114044A (zh) | 一种人工加工熊胆粉及其制备方法 | |
US10813961B2 (en) | Powder formulation having a function of enhancing immunity and method for preparing the same | |
CN104922586A (zh) | 一种防治鸡球虫病的益生菌发酵中药制剂的制备及其应用 | |
CN102895326B (zh) | 一种治疗小儿感冒的中药组合物及其制备方法 | |
CN102716223A (zh) | 一种治疗上呼吸道感染的中药组合物及其制备方法 | |
CN101332256B (zh) | 用于鸡传染性法氏囊炎的中药组合物及制备方法 | |
CN102754833B (zh) | 增强免疫力的保健品及其制备方法 | |
CN101181561B (zh) | 一种中药组合物及其制备方法和应用 | |
CN103961614A (zh) | 用于治疗呼吸***疾病的中药组合物及其制备方法和用途 | |
CN115105502B (zh) | 一种含千金藤属植物生物碱的化合物在制备猫传染性腹膜炎药物中的应用 | |
CN104367673B (zh) | 一种治疗鸡球虫的中药组合物 | |
CN103689599B (zh) | 增强免疫力的保健食品及其制备方法 | |
CN103082286B (zh) | 增强免疫力的保健食品及其制作方法 | |
CN106309758A (zh) | 一种抗胃肠癌的药物组合物 | |
CN103417653B (zh) | 一种治疗球虫的兽用复方纯中药及其口服液的制备方法 | |
CN112516276A (zh) | 预防新型冠状病毒肺炎的中药及其制备工艺和中药饮品 | |
CN102397458A (zh) | 一种治疗老年人肺炎的药物组合物及其制备方法 | |
CN101366852B (zh) | 治疗鸭疫里氏杆菌病的中草药物及其制备方法 | |
CN101904500B (zh) | 一种增强免疫力的功能食品及其制备方法 | |
CN105815786A (zh) | 一种双花黄精片剂及其制备方法 | |
CN110051765A (zh) | 一种治疗咳嗽的药物、制备方法及应用 | |
CN109876082A (zh) | 养阴清肺膏及其制备方法 | |
CN108498655A (zh) | 一种用于清热解毒的蓝金口服液及其制备方法 | |
CN101361846A (zh) | 一种用于治疗内科实火证类的解毒清热中药及制作方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Health food capable of enhancing immunity and preparation method thereof Effective date of registration: 20160311 Granted publication date: 20150429 Pledgee: Suiyang Bei Bei Village Bank Co., Ltd. Pledgor: Guizhou Sanrentang Pharmaceutical Co., Ltd. Registration number: 2016990000200 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20170116 Granted publication date: 20150429 Pledgee: Suiyang Bei Bei Village Bank Co., Ltd. Pledgor: Guizhou Sanrentang Pharmaceutical Co., Ltd. Registration number: 2016990000200 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model |